Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DNAPrint Genomics has revealed that KBI BioPharma has been selected as the company's good manufacturing practices manufacturer of PT-401, a more powerful form of the anemia drug Erythropoietin.
Subscribe to our email newsletter
The company obtained an exclusive, worldwide license from Harvard Medical School’s Beth Israel Deaconess Medical Center in February 2005 for the development of a “super” EPO, a more potent and longer acting form of Erythropoietin.
“GMP (good manufacturing practices) manufacturing is the next step in our R&D of PT-401,” stated DNAPrint president and CEO Richard Gabriel. “The GMP material produced by KBI BioPharma will be used to conduct preclinical studies required for a future investigational new drug application, including toxicology studies and studies involving volunteers and patients.”
The company’s goal is to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called “theranostics,” designed to maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors.